Discover What's
Next in
Cardiovascular Care.
Experience breakthrough Nanolute™ sirolimus-coated balloon technology — backed by landmark NEJM and JACC publications. Meet our experts at Booth F18, Paris.
Join Our Symposium
Deep dive into a session on sirolimus-coated balloon evidence and real-world procedural experience featuring global faculty with expert case discussions.
Where Evidence Meets Experience
Revolutionizing Drug Delivery in Vascular Intervention
NANOLUTE technology delivers polymer-free nanocarriers containing sirolimus surrounded by an encapsulation of a proprietary phospholipid carrier — improving lipophilicity and ensuring deep vessel wall penetration.
- Facilitates better adhesion of Sirolimus on the balloon surface
- Circumferential coating ensures homogeneous drug delivery
- Effective drug transfer to the deepest layer of the vessel
- Better in-tissue bioavailability of Sirolimus
A Decade
of Evidence
From CE Mark to a still-growing clinical record across coronary and peripheral indications.
MagicTouch
It's repeatedly studied.
Landmark Clinical Results
Randomised controlled trials demonstrating superior outcomes across coronary and peripheral indications — from JACC to the New England Journal of Medicine.
1. Log–rank p=0.03 | HR 0.60 (95% CI, 0.36–0.97). Preliminary before CEC adjudication.
MALE: Major Adverse Limb Events
2. –4.9% (–8.5% to –1.3%) P<0.001 for noninferiority | P=0.009 for superiority. Median Unbiased Estimate (95% CI).
3. Data published in EuroIntervention Journal: DOI: 10.4244/EIJ-D-23-00966, Volume 20, Number 13.
Meet Our Experts
at Booth F18
Schedule time with our clinical and commercial team for a personalised demo, data review, or strategic discussion.